GRI logo

GRI Bio, Inc.

GRI
Healthcare|Biotechnology|US
$1.88
+0.33 (+21.29%)
DCF Value
$65.34
Tangible Book / Share
$5.70
Cash / Share
$6.06
Next Earnings Report
Nov 13, 2026
EPS est. -$0.84
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Recent Press Releases

GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit
Sep 28, 2026 · GlobeNewsWire
GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars
Sep 8, 2026 · GlobeNewsWire
GRI Bio Featured in "Why Now" On-Demand Video Webcast
Aug 27, 2026 · GlobeNewsWire
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
Aug 24, 2026 · GlobeNewsWire

SEC Filings (6)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 4, 20268-KMaterial eventDocumentIndex
Sep 28, 2026ARSAnnual report to holdersDocumentIndex
Sep 28, 2026DEF 14AProxy / shareholder voteDocumentIndex
Sep 8, 20268-KMaterial eventDocumentIndex
Aug 14, 202610-QQuarterly reportDocumentIndex
Aug 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex